Ignatova G L, Antonov V N, Makarova E A, Kochetkova S A
South Ural State Medical University.
Regional Clinical Hospital №3.
Ter Arkh. 2020 Sep 3;92(8):95-99. doi: 10.26442/00403660.2020.08.000718.
The article provides data on modern approaches to the treatment of patients with severe uncontrolled bronchial asthma with an emphasis on the use of dupilumab, a human recombinant monoclonal antibody to the alpha subunit of the interleukin (IL)-4 receptor, which inhibits signal transmission from both IL-4 and IL-13. The results of dupilumab pivotal randomized clinical trials DRI12544, QUEST and VENTURE are summarized. Indications for use of this medicinal product are listed in Federal Clinical Guidelines on the management of asthma (year of revision 2019). Clinical cases with various clinical course of bronchial asthma are described, including cases with frequent exacerbations. In conclusion, dupilumab could be a treatment of choice for the patients with severe bronchial asthma and it is reasonable from an economic, clinical and pathogenetic point of view.
本文提供了关于重度未控制支气管哮喘患者现代治疗方法的数据，重点介绍了度普利尤单抗的使用，它是一种针对白细胞介素（IL）-4受体α亚基的人重组单克隆抗体，可抑制IL-4和IL-13的信号传导。总结了度普利尤单抗关键随机临床试验DRI12544、QUEST和VENTURE的结果。该药品的使用指征列于《哮喘管理联邦临床指南》（修订年份2019年）中。描述了支气管哮喘各种临床病程的临床病例，包括频繁发作的病例。总之，从经济、临床和发病机制角度来看，度普利尤单抗可能是重度支气管哮喘患者的首选治疗药物。
